Thyroid Tablets Recalled

On Aug. 21, 2026, Vitruvias Therapeutics, Inc. initiated a voluntary recall for one lot of Thyroid Tablets, USP 30mg. The recall was prompted by testing that confirmed the potential for the product to be superpotent, which can cause hyperthyroidism (overactive thyroid), including weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, or heart rhythm disturbances; patients at greatest risk include the elderly, pregnant women and infants. To date, no adverse events related to this recall have been reported. Thyroid is a natural preparation derived from desiccated porcine thyroid glands (composed of levothyroxine and liothyronine), FDA-indicated for the treatment of hypothyroidism (underactive thyroid). For more information about the recall, see here.